View All Resources
Article2
Source: Karolina Grabowska / Pexels

Early Access to New Products,
e-books & insights

By entering your email you agree to our privacy policy.

Jul 1, 2022

PT-141 Dosage Chart

What is the ideal dosage of PT-141 to maintain sexual health? This depends on the individual needs of the person taking this medication; hence, it is always recommended that you get PT-141 via a prescription from a qualified doctor who specializes in urology and men’s health. This is to ensure that you are not taking a dose of the drug that is too low or too high.

The very first time PT-141 was experimented on (as melanotan II), the dose was 10 mg. For some subjects this caused a long-lasting erection. Hence, researchers have lowered the dose in the hopes of achieving a more modest response. At about 1.25 mg, an erection can be achieved upon additional sexual stimuli.

Since then, scientists have researched the properties of PT-141 at various doses. For example, one clinical trial investigated the properties of PT-141 between 0 mg (placebo) to 10 mg. The route of administration in this study was intranasal (through the nose).

The LOVER Protocol by Maximus contains PT-141 at a dose of 2000 mcg. Crucially, it also contains tadalafil 5 mg. This allows PT-141 to work synergistically with tadalafil to help you develop and maintain erections.

The LOVER Protocol also differs from typically available PT-141 in that it is packaged in the form of a tablet. It is orally dissolved and fast-acting. This means no nasty injections that can give you swelling or bruising.

In addition, the LOVER Protocol is meant to promote sexual health in general. This means that it is not to be taken only before a sexual encounter, but on a regular basis.

The LOVER Protocol by Maximus contains PT-141 2000 mcg and tadalafil 5 mg. It is intended to boost your sexual health and performance for the immediate and longterm.


References

Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689. doi:10.1016/j.peptides.2005.01.023

Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. doi:10.1038/sj.ijir.3901200

Disclaimer: The contents of this article, including, but not limited to, text, graphics, images, and other information, is for information purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. The content is not meant to be complete or exhaustive or to be applicable to any specific individual's medical condition. You should consult a licensed healthcare professional before starting any health protocol and seek the advice of your physician or other medical professional if you have questions or concerns about a medical condition. Always talk to your doctor about the risks and benefits of any treatment. Never disregard or delay seeking professional medical advice or treatment because of something you have read on this site. Maximus does not recommend, endorse, or make any representation about the efficacy, appropriateness, or suitability of any specific test, products, procedures, treatments, services, opinions, healthcare providers or other information contained herein. Maximus is not responsible for, nor will they bear any liability for, the content provided herein or any actions or outcomes resulting from or related to its use.

View All Resources

Early Access to New Products,
e-books & insights

By entering your email you agree to our privacy policy.